STRATEC’s Annual General Meeting resolves on dividend increase
Birkenfeld, June 6, 2013
At today’s Annual General Meeting of STRATEC Biomedical AG (Frankfurt: SBS; Prime Standard, TecDAX), all items on the meeting’s agenda requiring a vote were approved.
The dividend increase endorsed at the Annual General Meeting represents the tenth successive rise that STRATEC has distributed to shareholders since the company started making dividend payments.
For the 2012 financial year, STRATEC will distribute a dividend of € 0.56 per share (previous year: € 0.55) to its shareholders, corresponding to a total distribution of € 6.6 million. The dividend will be distributed to shareholders via their custodian banks as of June 10, 2013.
STRATEC’s management supported a shareholder motion proposed during the Annual General Meeting to increase the dividend to € 0.56. The proposed resolution by management initially envisioned a dividend distribution of € 0.50.
At the beginning of his speech at the Annual General Meeting, Marcus Wolfinger, Chairman of the Board of Management, stated, “In light of current information, and due to the improved overall situation since our initial proposal, we fully support today’s motion to increase the dividend as it enables STRATEC to continue its series of ever-larger dividend payouts, which so far stands at ten in succession.”
The Annual General Meeting also saw the approval of the Board of Management’s compensation system plus the new compensation structures for members of the Supervisory Board. Resolutions were also approved regarding a new stock option program and a corporate contract.
Further information on STRATEC’s Annual General Meeting is available at www.stratec.com > Investor Relations > Annual General Meeting.
STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies. Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange, and are a constituent of the Deutsche Börse TecDAX.
Further information can be obtained from:
STRATEC Biomedical AG
André Loy, Investor Relations
Gewerbestr. 37, 75217 Birkenfeld
Phone: +49 7082 7916 190
Fax: +49 7082 7916 999